G6047 HCPCS Level II code: Dihydrotestosterone
CMS terminated G6047: its last date of service was Dec 31, 2015. It stays here for looking up older claims; newer services need a current code.
Official description
G6047Dihydrotestosterone
Short description: Assay of dihydrotestosterone
HCPCS · United States
Medicare details
The indicators CMS publishes with G6047 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Clinical lab fee schedule – Price subject to national limitation amount
- Type of service
- Diagnostic laboratory
- BETOS category
- Lab tests - other (Non-Medicare fee schedule)
- Lab certification
- Endocrinology
- Added
- Jan 1, 2015
- Terminated after
- Dec 31, 2015
Where G6047 sits
- 1G codesProcedures and professional services
- 2Terminated G6047Dihydrotestosterone
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code G6047 still valid?
No. CMS terminated G6047; its last date of service was Dec 31, 2015. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover G6047?
CMS lists G6047’s Medicare coverage as “Carrier judgment” and its pricing as “Clinical lab fee schedule – Price subject to national limitation amount”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.